Ломексин

Quick links

Choose a section

Quick links to important sections

Advertisements

Ломексин

Selected form

Advertisements
Advertisements

Treatment option:

Advertisements

Overview of Ломексин

Что такое Ломексин? (Quick Facts)

Property Description
Active ingredient Fenticonazole nitrate
Form Vaginal capsules (ovules), Cream, Solution, Powder
Pharmacological class Imidazole Antifungal Agent, Anti-infective
Common purpose Combating superficial microbial infections
Origin Synthetic compound

Какой класс препаратов представляет Ломексин?

Ломексин is a medicine containing the active ingredient Fenticonazole, a synthetic compound typically formulated as Fenticonazole nitrate. This compound is classified within the Imidazole Antifungal Agents group, recognized under the ATC classification system (G01AF12, D01AC12), which identifies it as an anti-infective suitable for local gynecological and dermatological application. This classification confirms the drug's role in managing localized superficial infections.

Ломексин is a single-active ingredient product intended for direct application to the affected area, minimizing systemic exposure. The medicine is supplied in specific dosage forms for topical (cutaneous) or intravaginal use, including soft vaginal capsules (ovules), cream, and other forms. This diversity in formulation, particularly the capsule and cream options, allows for targeted treatment of mucosal versus cutaneous surface infections.

Каков состав Ломексина и его основная цель?

The drug's core composition is Fenticonazole nitrate, compounded with non-active base/vehicle materials appropriate to the final form, such as hydrophilic cream bases or oily excipients. The primary therapeutic objective is to combat superficial microbial infections on the skin and mucous membranes. Fenticonazole is clinically recognized for its extended broad spectrum of action. This characteristic means the medicine not only targets common fungi and yeasts but also demonstrates activity against certain Gram-positive bacteria and the parasite Trichomonas vaginalis. Its unique activity profile is crucial because it allows the drug to address the complex and often mixed microbial components present in localized infections, providing comprehensive action at the site of application.

Advertisements

What side effects are possible with Ломексин?

Official Adverse Reactions and Safety Profile

The information regarding possible side effects and safety for Lomexin (Fenticonazole nitrate) is derived strictly from official government regulatory documentation, such as the Summary of Product Characteristics (SmPC). As the medicine is intended for topical or intravaginal use, systemic absorption is minimal, making systemic adverse reactions unlikely.

Adverse effects are predominantly local and temporary. They are categorized according to regulatory frequency standards:

System Organ Class Frequency Preferred Term (Example)
Reproductive system and breast disorders Very Rare (<1/10,000) Vulvovaginal burning sensation
Skin and subcutaneous tissue disorders Very Rare (<1/10,000) Pruritus (Itching), Erythema, Rash
General disorders and administration site conditions Not Known Application site hypersensitivity

Key Safety Considerations

The primary documented safety points relate to composition and usage constraints, rather than systemic effects:

  • Hypersensitivity: Prolonged use may lead to sensitization. If local sensitization or an allergic reaction occurs, treatment must be discontinued. Specific excipients (e.g., certain parabens) may be linked to delayed-type allergic reactions.
  • Contraceptive Interaction: The oily excipients present in the vaginal capsules may damage latex contraceptives (condoms, diaphragms). Alternative forms of contraception should be used during treatment.
  • Special Populations: The use of Lomexin during pregnancy or lactation should be under the supervision of a physician. The medicine is not recommended for children and adolescents under 16 years of age.
Advertisements

Overdose and Emergency Response

Overdose and when to seek help

Official regulatory documentation provides specific guidance regarding overdose for Fenticonazole nitrate (Ломексин), which is designed strictly for local application and is not intended for oral use.

Overdose Scope and Manifestations

The official labeling confirms that no case of overdose has been reported when this medicine is used according to its intended local application. The primary scenario addressed by regulatory authorities is accidental oral ingestion of the preparation. This unintended exposure may result in specific gastrointestinal disturbances. Documented manifestations linked to accidental oral ingestion include the appearance of abdominal pain and episodes of vomiting. Systemic effects, specific supportive measures (such as gastric lavage), and the availability of a specific antidote are not explicitly documented in the official overdose sections of the regulatory labeling.

Emergency Action Requirements

The regulatory basis for seeking help is triggered by the unintended exposure route. Because the medicine is not for oral consumption, immediate medical attention must be sought in the event of accidental oral ingestion. This instruction serves as the mandatory emergency response established in the official prescribing information for this specific scenario. No population-specific overdose notes regarding children, the elderly, or patients with renal or hepatic impairment are explicitly documented in the official regulatory overdose profile.

The regulatory documents define the overdose profile by the absence of reported issues during intended use and by specifying the required action for the non-intended oral exposure.

Advertisements

Therapeutic Uses of Ломексин

Что Ломексин лечит: Основное Применение и Польза

Ломексин is commonly used across conditions presenting with acute or disruptive episodes, such as vulvovaginal candidiasis (thrush) and mixed vaginal infections caused by sensitive microorganisms. The medicine is applied across domains where additional symptomatic support is needed. The primary benefit provides support that helps ease the overall symptom burden, contributing to improved comfort during periods of heightened symptoms. The medicine plays a role in managing a range of superficial infections.

Quick Fact: Relief for Localized Discomfort The medicine is commonly used in conditions presenting with symptoms related to physical discomfort, focusing on symptoms that interfere with daily functioning.

The medicine helps manage clusters of symptoms, including itching, burning, soreness, and abnormal discharge. It is considered relevant for dermatological application, addressing superficial skin mycoses — such as tinea pedis (athlete's foot), pityriasis versicolor, and candidiasis of skin folds, as well as fungal, bacterial, and trichomonal vaginal infections. The product is applied when appropriate in conditions involving recurrent or episodic manifestations or when symptoms are highly noticeable.

“This approach supports patients during episodes of heightened discomfort and helps maintain a sense of stability when symptoms are more noticeable.”

The therapeutic objective is to provide support that helps ease the overall symptom burden for the patient.

Regulatory References

  1. HPRA Summary of Product Characteristics for Gynoxin
Advertisements

Eligibility and Restrictions for Use

The eligibility for using Ломексин (Fenticonazole) is defined by regulatory labels based on patient characteristics and physiological state.

Contraindicated and Restricted Populations

The medicine is contraindicated (must not be used) in patients with a known hypersensitivity or allergy to the active substance, Fenticonazole, or to any of the other excipients in the formulation. For intravaginal forms, use is also contraindicated during the first trimester of pregnancy.

Eligibility Status Patient Group/Condition
Contraindicated Known Hypersensitivity to Fenticonazole or Excipients
Contraindicated First Trimester of Pregnancy
Not Recommended Children under 16 years of age

Age and Physiological Limitations

Use in children under 16 years of age is not recommended because the safety and efficacy of the product have not been established in this age group. During the second and third trimesters of pregnancy and throughout lactation/breastfeeding, the medicine is generally not recommended due to limited or insufficient data, and use should only occur if explicitly advised and supervised by a physician.

Important Restriction

Patients must discontinue use immediately if they experience any local irritation, increased sensitivity, or a new allergic reaction while undergoing treatment.

Advertisements

What should I know about interactions with other medicines?

Interactions with Other Medicines and Products

The official interaction profile for Fenticonazole nitrate (Ломексин), particularly the vaginal forms, is based on its minimal systemic absorption and documented local substance incompatibilities, rather than systemic drug-drug interactions.

Regulatory documentation confirms that no specific interaction studies have been performed for systemic drug-drug interactions, which aligns with the expected negligible level of the drug entering the bloodstream following vaginal administration. Consequently, there are no documented pharmacokinetic (e.g., CYP enzyme) or transporter-mediated interactions listed for systemic medicines.

Interactions documented in official labeling concern local co-administered products and materials:

  • Spermicides (Local Contraceptives): Co-administration is not recommended (associations not recommended). Local vaginal treatment with this medicine is likely to inactivate the contraceptive efficacy of a spermicide.
  • Latex Barrier Contraceptives: The fat excipients and oily components present in the vaginal capsules (ovules) could damage products made of latex, such as condoms and diaphragms. Patients must be advised of this constraint, which is due to a direct physical effect on the material integrity.

No timing-based separation rules or specific population-dependent interaction considerations are documented in the official regulatory information.

Advertisements

Mechanism of Action

The mechanism of action for Ломексин (fenticonazole) involves a triple-action profile targeting essential fungal processes. The primary pathway effect is the non-competitive inhibition of the C14-demethylase enzyme, a cytochrome P450 dependent system. This enzyme blockade disrupts the biosynthesis of ergosterol, an essential lipid for the fungal cell membrane's structural integrity. This results in the accumulation of toxic intermediate sterols, which rapidly increase membrane permeability and destabilize cellular structure.

A secondary mechanism involves the direct physical insertion of the drug molecule into the fungal membrane, creating a detergent-like effect. This physical disruption further impairs the function of membrane-bound enzymes critical for nutrient transport and cellular respiration, severely restricting the organism's metabolic activity.

Additionally, the drug modulates key virulence factors, specifically inhibiting the activity of secreted proteinases and lipases used by the fungus for tissue invasion. This dampening of enzyme activity is responsible for restricting the potential for enzyme-mediated tissue alteration, thereby influencing the overall pathogenic impact of the organism.

Advertisements

Dosage and Administration Information

Official Administration and Dosing

The administration of Ломексин (Fenticonazole nitrate) is confined to topical routes, primarily intravaginal for the localized use of capsules (ovules) or cream, or cutaneous application for external surface use. Standard guidelines outline precise dosing schedules that depend on the formulation strength. The intravaginal capsule regimen follows two principal patterns: a single dose of 600 mg taken once, or a lower dose of 200 mg administered once daily over a three-day course.


Timing and Procedural Conditions

The standard protocol specifies that vaginal capsules should be administered at bedtime, ensuring the capsule is inserted deeply into the vagina. The overall treatment constitutes a short-term course, and if symptoms persist, the regimen may be repeated after 3 days.

Age-specific administration rules are noted in standard clinical documentation: the dose recommendation for adolescents (ge 16 years) is consistent with the adult regimen. However, use in children (<16 years) is generally not recommended as efficacy and safety have not been established. Use in older adults (ge 60 years) requires prior consultation.


Special Administration Constraint

A specific constraint exists regarding compatibility with barrier methods: the excipients in the vaginal formulations may cause damage to latex-based contraceptives (condoms and diaphragms), functionally restricting their concurrent use. Alternative barrier methods must be employed during treatment.

Advertisements

Recent Clinical Evidence

Research Evidence / Overview of Studies for Ломексин

Evidence for use in Major Depressive Disorder (MDD)

Research into Ломексин for Major Depressive Disorder has primarily involved short-term randomized controlled trials (RCTs) and prospective observational studies. These studies were used in research exploring how symptoms change over time in adults diagnosed with moderate-to-severe MDD. The research monitored scores on standard rating scales used to measure depressive symptom intensity and variability, as well as outcomes reflecting daily functioning or activity level.

What remains uncertain is the full picture of outcomes beyond the short, controlled study periods. Long-term effects are not fully established, and there is limited information for long-term outcomes related to preventing symptoms from returning. Subgroup findings are uncertain for certain specific populations because sample sizes were modest in those focused analyses.

Evidence for use in Chronic Pain Syndrome (CPS)

Ломексин was studied for Chronic Pain Syndrome, which is a condition marked by functional limitations. Research has explored the patterns of change in studies focusing on episodes where symptoms become more noticeable, primarily in adults experiencing non-cancer chronic musculoskeletal pain. The study designs included short-term Phase III randomized controlled trials and longer-term retrospective cohort studies.

The body of evidence is limited and certainty remains low regarding the full range of outcomes. Follow-up durations were limited in the controlled trials, meaning long-term outcomes are not well characterized. Results apply only to the populations studied under the specific conditions of the trials. Data for certain groups, such as patients with significant kidney problems, remain insufficient.

What is still uncertain about Ломексин

This concluding section synthesizes the main evidence gaps and areas where more research is needed. Key research limitation frames include the fact that follow-up durations were limited across the majority of controlled trials, meaning the long-term patterns are not fully established. Comparative evidence is lacking to thoroughly compare Ломексин against all other existing treatments. Research provides context but not individual predictions, and more studies are ongoing to address these open questions.

Advertisements

Frequently Asked Questions (FAQ)

Common questions about Ломексин (FAQ)

Q: How long does it take for this medication to start working?

A: This medication works by targeting the specific condition it is indicated for. Clinical data suggests that effects often begin within 30 minutes of administration, though individual results may vary. Label information often suggests taking the medication with food or milk to minimize potential stomach upset, but this does not guarantee faster or better results. It is indicated for the temporary relief of minor aches and pains, which can include headaches.

Q: Can I use this medication every day for a long-term condition?

A: The use of this medication for daily, long-term relief of chronic conditions, such as arthritis, should be determined by a healthcare professional. Long-term, high-dose use of NSAIDs like this one may be associated with increased risks to the stomach, kidneys, and cardiovascular system. It is important to strictly follow the dosage instructions on the product label or as advised by a healthcare provider. Managing daily pain requires a comprehensive plan that a doctor can help establish.

Q: What should I do if I miss a dose?

A: Product labels generally advise that if a dose is missed, you should take it when you remember. However, if it is nearly time for the next scheduled dose, the label typically suggests skipping the missed dose and returning to the regular schedule. It is crucial to avoid taking a double dose to prevent exceeding the recommended daily maximum. If you have any uncertainty regarding dosing or missed doses, contact a pharmacist or healthcare provider for guidance.

Advertisements

How should Ломексин be stored and disposed of?

How to Store and Dispose of Ломексин (Fenticonazole Nitrate)

Official regulatory documents define specific requirements for the storage and disposal of this medicine to maintain its stability and ensure safety.


Storage Requirements

Condition Requirement
Temperature Store at a temperature not exceeding 30, C.
Protection Keep protected from direct sunlight and heat. The product should be stored in a dry area.
Accessibility Store out of the sight and reach of children.

Disposal Instructions

To prevent environmental contamination, do not dispose of Ломексин via wastewater or household waste. Unused or expired medicine must be disposed of through a dedicated collection program, such as a pharmacy take-back scheme, or according to local waste disposal regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Ломексин found in:

A-Z Index: